TXA Central
TXA Central is a resource for health professionals caring for patients with acute severe bleeding
Category: Uncategorized
Injured Women Half as Likely as Men to Receive Tranexamic Acid
New research has found that female trauma patients are half as likely as men to receive tranexamic acid – even though the treatment is equally effective regardless of sex. This highlights the urgent need to improve equity in trauma care. Read the full article here.
Details
Cost-effectiveness of TXA for older adults experiencing mild traumatic brain injury
Mild traumatic brain injury in older adults is a huge problem in the UK. Finding out if tranexamic acid improves outcomes is well worth the cost according to recent economic modelling. The CRASH-4 trial will answer this important question. Read the full article here.
Details
Healthy volunteer trial looking at pharmacokinetics of TXA in alternate routes, shows IM TXA to be an efficient alternative to IV
Background: In response to the World Health Organization call for research on alternative routes for tranexamic acid(TXA) administration in women with postpartum haemorrhage, we examined the pharmacokinetics of TXA after i.v., i.m., or oral administration.Methods: We conducted a randomised, open-label, crossover trial in 15 healthy volunteers who received i.v. TXA 1 g, i.m. TXA 1
Details
‘HER LIFE MATTERS’ DOCUMENTARY IS LIVE
This documentary ‘Her Life Matters’ asks why each year, world-wide tens of thousands of mothers bleed to death needlessly – lives that could be saved by a single injection of an inexpensive generic drug called tranexamic acid. Tranexamic acid was invented sixty years ago to stop mothers from bleeding to death after childbirth. The Woman trial showed that timely treatment
Details
WOMAN-2 Trial
The WOMAN-2 trial investigates Tranexamic Acid (TXA) for the prevention of postpartum bleeding in women with anaemia: an international, randomised, double-blind, placebo-controlled trial.
Details
Art for Maternal Health Awareness
Healthcare is a human-right. Sculpture artist, Moira Purver was commissioned by the WOMAN trial to create this spectacular bronze statue, appropriately titled WOMAN, that depicts a mother on her knees holding her new baby in her arms just after giving birth. Every year 14 million mothers develop severe bleeding after childbirth or postpartum haemorrhage (PPH)
Details
A CRASH-3 Trial Sub-Study Provides Evidence of TXA Benefit in TBI
This sub-study found that when patients with unreactive pupils at baseline were excluded, there was evidence that TXA prevents new haemorrhage (adjusted RR=0.80, 95% CI 0.66 to 0.98).
Details
World Day of Remembrance for Road Traffic Victims
Even though evidence on the benefits of TXA in trauma has been available for over a decade, most trauma victims are still not being treated with TXA soon enough, if at all.
Details
WOMAN-PharmacoTXA Trial
The WOMAN-PharmacoTXA trial is a randomised controlled trial to assess the pharmacokinetics and pharmacodynamics of intramuscular, intravenous, and oral administration of tranexamic acid in women giving birth by caesarean section
Details
World Health Organization reacts to the WOMAN Trial results
In response to the release of the WOMAN trial results, the World Health Organisation (WHO) department of reproductive health and research is working with the Cochrane Pregnancy and Childbirth group to fast-track the update of the existing Cochrane systematic review on the treatment of primary postpartum hemorrhage (PPH) with priority given to the use of
Details- 1
- 2